| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
458,423 |
392,435 |
$52.16M |
| 96361 |
Intravenous infusion, hydration; each additional hour |
46,839 |
36,452 |
$18.36M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
262,907 |
239,861 |
$17.09M |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
83,400 |
74,255 |
$17.07M |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
88,969 |
80,108 |
$14.73M |
| G0378 |
Hospital observation service, per hour |
62,234 |
42,893 |
$12.14M |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
46,357 |
37,039 |
$10.86M |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
239,487 |
227,495 |
$10.38M |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
58,185 |
52,851 |
$8.35M |
| J9271 |
Injection, pembrolizumab, 1 mg |
1,975 |
1,516 |
$7.57M |
| 96413 |
Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance |
40,357 |
24,679 |
$6.28M |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
296,765 |
228,223 |
$5.74M |
| 90834 |
Psychotherapy, 45 minutes with patient |
100,269 |
49,769 |
$5.69M |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
109,856 |
51,280 |
$5.53M |
| 77386 |
|
24,017 |
2,311 |
$5.17M |
| 43239 |
Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple |
8,485 |
8,218 |
$4.99M |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
81,937 |
71,819 |
$4.59M |
| 96366 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour |
19,370 |
15,350 |
$4.57M |
| J1569 |
Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg |
3,298 |
1,373 |
$4.45M |
| 99215 |
Prolong outpt/office vis |
49,649 |
43,683 |
$3.98M |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
30,155 |
28,361 |
$3.45M |
| Q5103 |
Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg |
2,928 |
2,025 |
$3.16M |
| 45385 |
Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) |
4,937 |
4,859 |
$3.06M |
| 70450 |
Computed tomography, head or brain; without contrast material |
22,755 |
20,710 |
$3.04M |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
35,550 |
31,199 |
$3.01M |
| J3380 |
Injection, vedolizumab, intravenous, 1 mg |
1,280 |
1,139 |
$3.01M |
| S9485 |
Crisis intervention mental health services, per diem |
5,210 |
4,181 |
$2.99M |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
42,027 |
38,047 |
$2.98M |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
46,894 |
38,714 |
$2.93M |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
19,117 |
18,426 |
$2.85M |
| 45380 |
Colonoscopy, flexible; with biopsy, single or multiple |
4,829 |
4,714 |
$2.82M |
| 96375 |
Therapeutic injection; each additional sequential IV push |
56,115 |
40,938 |
$2.75M |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
19,164 |
16,456 |
$2.75M |
| 70553 |
Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences |
8,747 |
8,321 |
$2.62M |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
37,698 |
34,285 |
$2.59M |
| J9312 |
Injection, rituximab, 10 mg |
1,087 |
648 |
$2.58M |
| J1745 |
Injection, infliximab, excludes biosimilar, 10 mg |
2,808 |
1,607 |
$2.57M |
| J2357 |
Injection, omalizumab, 5 mg |
2,704 |
1,619 |
$2.54M |
| 96415 |
|
10,837 |
7,445 |
$2.36M |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
43,179 |
33,762 |
$2.31M |
| 92507 |
Treatment of speech, language, voice, communication, and/or auditory processing disorder |
18,244 |
8,065 |
$2.23M |
| J2315 |
Injection, naltrexone, depot form, 1 mg |
2,296 |
2,056 |
$2.20M |
| Q9992 |
Injection, buprenorphine extended-release (sublocade), greater than 100 mg |
1,457 |
1,374 |
$2.10M |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
15,472 |
14,881 |
$2.04M |
| 77412 |
|
13,808 |
1,772 |
$2.01M |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
49,778 |
41,840 |
$1.96M |
| J9035 |
Injection, bevacizumab, 10 mg |
1,580 |
493 |
$1.91M |
| J9355 |
Injection, trastuzumab, excludes biosimilar, 10 mg |
1,468 |
723 |
$1.89M |
| 99291 |
Critical care, evaluation and management of the critically ill patient, first 30-74 minutes |
7,096 |
6,701 |
$1.76M |
| 95810 |
Polysomnography; sleep staging with 4 or more additional parameters |
2,073 |
1,981 |
$1.71M |
| J2350 |
Injection, ocrelizumab, 1 mg |
129 |
113 |
$1.67M |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
25,430 |
22,776 |
$1.65M |
| 70551 |
Magnetic resonance imaging, brain; without contrast material |
6,213 |
5,907 |
$1.60M |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
14,167 |
13,517 |
$1.59M |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
27,287 |
26,974 |
$1.56M |
| 71275 |
Computed tomographic angiography, chest, with contrast material |
8,138 |
7,688 |
$1.52M |
| Q5115 |
Injection, rituximab-abbs, biosimilar, (truxima), 10 mg |
746 |
427 |
$1.51M |
| 93971 |
|
8,738 |
8,121 |
$1.44M |
| 71046 |
Radiologic examination, chest; 2 views |
64,393 |
59,811 |
$1.42M |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
332,926 |
261,129 |
$1.41M |
| J9144 |
Injection, daratumumab, 10 mg and hyaluronidase-fihj |
1,378 |
822 |
$1.37M |
| 97535 |
Self-care/home management training, each 15 minutes |
21,183 |
15,479 |
$1.33M |
| 76856 |
Ultrasound, pelvic (nonobstetric), real time with image documentation; complete |
12,400 |
12,023 |
$1.33M |
| 78812 |
|
1,765 |
1,677 |
$1.32M |
| J2505 |
Injection, pegfilgrastim, 6 mg |
978 |
648 |
$1.32M |
| J3490 |
Unclassified drugs |
46,913 |
32,073 |
$1.31M |
| 78452 |
Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress |
4,506 |
4,362 |
$1.31M |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
9,785 |
9,092 |
$1.26M |
| 78815 |
Positron emission tomography (PET) for limited area imaging |
1,693 |
1,603 |
$1.26M |
| 99201 |
|
11,883 |
11,129 |
$1.25M |
| 71260 |
Computed tomography, thorax, diagnostic; with contrast material |
18,090 |
17,188 |
$1.25M |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
42,590 |
35,647 |
$1.22M |
| 93308 |
|
6,424 |
6,088 |
$1.19M |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
12,359 |
11,622 |
$1.16M |
| Q5108 |
Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg |
500 |
325 |
$1.12M |
| 96367 |
|
10,982 |
8,422 |
$1.08M |
| 76770 |
|
7,426 |
7,197 |
$1.08M |
| 36430 |
|
5,708 |
3,210 |
$1.07M |
| 90651 |
|
10,099 |
9,985 |
$1.06M |
| 99205 |
Prolong outpt/office vis |
8,052 |
7,429 |
$1.05M |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
41,291 |
39,447 |
$1.01M |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
41,077 |
39,241 |
$1.01M |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
63,380 |
55,034 |
$1.00M |
| 76830 |
Ultrasound, transvaginal |
11,341 |
10,999 |
$1.00M |
| J9263 |
Injection, oxaliplatin, 0.5 mg |
4,468 |
1,645 |
$991K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
48,958 |
22,860 |
$982K |
| 76700 |
Ultrasound, abdominal, real time with image documentation; complete |
7,361 |
7,167 |
$972K |
| 90832 |
Psychotherapy, 30 minutes with patient |
32,746 |
21,596 |
$949K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
49,761 |
34,055 |
$912K |
| 93970 |
|
4,776 |
4,554 |
$903K |
| 70496 |
|
4,007 |
3,813 |
$896K |
| J0185 |
Injection, aprepitant, 1 mg |
5,121 |
3,199 |
$885K |
| 77336 |
|
12,485 |
5,463 |
$847K |
| 43235 |
|
1,479 |
1,423 |
$832K |
| 74183 |
|
3,239 |
3,064 |
$824K |
| 71045 |
Radiologic examination, chest; single view |
30,825 |
26,584 |
$817K |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
13,108 |
12,277 |
$811K |
| J7307 |
Etonogestrel (contraceptive) implant system, including implant and supplies |
733 |
712 |
$806K |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
8,686 |
6,806 |
$782K |
| J1561 |
Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg |
1,004 |
421 |
$781K |
| 84443 |
Thyroid stimulating hormone (TSH) |
89,350 |
85,689 |
$766K |
| G0121 |
Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk |
1,285 |
1,266 |
$744K |
| 47562 |
|
301 |
270 |
$741K |
| 97112 |
Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination |
21,763 |
12,363 |
$725K |
| 97161 |
|
17,857 |
17,350 |
$722K |
| 59025 |
Fetal non-stress test |
2,925 |
2,388 |
$716K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
5,809 |
5,496 |
$706K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
42,019 |
40,661 |
$695K |
| Q0138 |
Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) |
2,097 |
1,449 |
$684K |
| 92610 |
|
5,777 |
5,393 |
$666K |
| 99396 |
Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years |
13,289 |
12,607 |
$664K |
| J0485 |
Injection, belatacept, 1 mg |
2,813 |
1,301 |
$661K |
| 77334 |
|
4,371 |
3,296 |
$656K |
| 76642 |
|
7,770 |
6,892 |
$654K |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
18,704 |
11,302 |
$653K |
| 45378 |
Colonoscopy, flexible; diagnostic, including collection of specimen(s) |
1,234 |
1,207 |
$651K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
109,510 |
91,937 |
$650K |
| 83735 |
|
167,436 |
117,023 |
$609K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
1,888 |
1,801 |
$605K |
| J0897 |
Injection, denosumab, 1 mg |
1,673 |
1,522 |
$599K |
| 95813 |
|
1,442 |
1,411 |
$595K |
| 77387 |
|
17,600 |
2,105 |
$586K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
59,714 |
56,902 |
$576K |
| Q9991 |
Injection, buprenorphine extended-release (sublocade), less than or equal to 100 mg |
881 |
802 |
$567K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
73,559 |
72,475 |
$565K |
| 86481 |
|
9,852 |
9,476 |
$555K |
| 90870 |
|
1,374 |
456 |
$550K |
| 99381 |
|
4,159 |
4,049 |
$547K |
| 97803 |
|
9,475 |
8,361 |
$544K |
| 77300 |
|
3,625 |
3,363 |
$541K |
| J2469 |
Injection, palonosetron hcl, 25 mcg |
5,680 |
3,272 |
$536K |
| 93017 |
|
7,495 |
7,199 |
$535K |
| 95811 |
|
724 |
692 |
$530K |
| 95782 |
|
501 |
490 |
$530K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
275,977 |
211,736 |
$527K |
| 85027 |
|
146,713 |
117,494 |
$523K |
| ATP15 |
|
64,190 |
48,588 |
$523K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
69,539 |
67,732 |
$520K |
| J2506 |
Injection, pegfilgrastim, excludes biosimilar, 0.5 mg |
429 |
312 |
$508K |
| 83880 |
|
25,185 |
22,631 |
$504K |
| 73564 |
|
15,140 |
13,484 |
$502K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
108,344 |
105,322 |
$500K |
| 75574 |
|
3,200 |
3,083 |
$489K |
| 76536 |
|
5,098 |
4,962 |
$483K |
| 77295 |
|
1,333 |
1,286 |
$471K |
| 87631 |
|
6,614 |
6,171 |
$468K |
| 90686 |
|
69,810 |
68,927 |
$463K |
| 84484 |
|
41,367 |
34,727 |
$459K |
| J7298 |
Levonorgestrel-releasing intrauterine contraceptive system (mirena), 52 mg |
527 |
512 |
$456K |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
27,773 |
27,049 |
$451K |
| J1950 |
Injection, leuprolide acetate (for depot suspension), per 3.75 mg |
620 |
568 |
$440K |
| S0302 |
Completed early periodic screening diagnosis and treatment (epsdt) service (list in addition to code for appropriate evaluation and management service) |
53,447 |
53,149 |
$439K |
| 90853 |
Group psychotherapy (other than of a multiple-family group) |
16,596 |
6,057 |
$420K |
| 88307 |
|
6,222 |
4,710 |
$420K |
| 76882 |
|
4,170 |
3,820 |
$418K |
| 87536 |
|
10,021 |
9,599 |
$415K |
| 97116 |
|
10,638 |
7,189 |
$413K |
| ATP14 |
|
56,663 |
44,783 |
$406K |
| J9395 |
Injection, fulvestrant, 25 mg |
857 |
735 |
$401K |
| J9217 |
Leuprolide acetate (for depot suspension), 7.5 mg |
1,242 |
1,178 |
$399K |
| 90791 |
Psychiatric diagnostic evaluation |
4,388 |
4,193 |
$394K |
| 29700 |
|
2,636 |
2,221 |
$381K |
| 73610 |
|
13,507 |
11,943 |
$376K |
| G0105 |
Colorectal cancer screening; colonoscopy on individual at high risk |
741 |
733 |
$371K |
| 97162 |
|
11,676 |
10,763 |
$368K |
| 72148 |
Magnetic resonance imaging, lumbar spine; without contrast material |
2,804 |
2,697 |
$367K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
11,394 |
10,191 |
$366K |
| J1453 |
Injection, fosaprepitant, 1 mg |
1,014 |
636 |
$360K |
| 71250 |
|
7,703 |
7,402 |
$359K |
| J9305 |
Injection, pemetrexed, not otherwise specified, 10 mg |
254 |
102 |
$357K |
| 73030 |
|
11,707 |
10,701 |
$355K |
| 93505 |
|
595 |
488 |
$350K |
| 87624 |
Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types |
16,325 |
16,016 |
$344K |
| 82728 |
|
46,588 |
43,730 |
$342K |
| ATP08 |
|
60,232 |
46,746 |
$342K |
| 96416 |
|
2,762 |
1,575 |
$341K |
| J9310 |
Injection, rituximab, 100 mg |
426 |
291 |
$331K |
| 97165 |
|
4,065 |
3,897 |
$327K |
| 88185 |
|
1,313 |
1,165 |
$327K |
| 62323 |
|
858 |
827 |
$325K |
| 70544 |
|
1,957 |
1,851 |
$322K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
64,239 |
58,242 |
$322K |
| 94375 |
|
7,567 |
7,068 |
$322K |
| 95886 |
|
1,665 |
1,596 |
$322K |
| J9306 |
Injection, pertuzumab, 1 mg |
118 |
90 |
$321K |
| 83605 |
|
34,440 |
28,855 |
$319K |
| 96401 |
|
3,892 |
2,108 |
$319K |
| 73630 |
|
14,396 |
12,688 |
$318K |
| 88175 |
Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer |
16,429 |
16,164 |
$312K |
| 72125 |
Computed tomography, cervical spine; without contrast material |
8,010 |
7,450 |
$312K |
| 80076 |
|
153,047 |
128,380 |
$311K |
| 77301 |
|
997 |
959 |
$307K |
| 20610 |
|
2,657 |
2,363 |
$297K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
27,340 |
27,030 |
$296K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
9,883 |
8,501 |
$296K |
| 97802 |
|
4,820 |
4,534 |
$295K |
| 86850 |
|
43,504 |
34,735 |
$290K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
13,677 |
12,789 |
$289K |
| J1756 |
Injection, iron sucrose, 1 mg |
4,256 |
2,142 |
$288K |
| 93975 |
|
2,990 |
2,828 |
$284K |
| 86780 |
|
28,487 |
27,596 |
$282K |
| 90847 |
Family psychotherapy with the patient present, 50 minutes |
3,167 |
2,172 |
$281K |
| 70491 |
|
3,162 |
2,945 |
$280K |
| 0001A |
|
9,853 |
8,869 |
$280K |
| J7050 |
Infusion, normal saline solution, 250 cc |
77,021 |
43,304 |
$277K |
| 72141 |
|
1,596 |
1,515 |
$277K |
| 72197 |
|
990 |
928 |
$275K |
| 93303 |
Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study |
1,115 |
1,070 |
$273K |
| 73721 |
Magnetic resonance imaging, any joint of lower extremity; without contrast material |
1,272 |
1,190 |
$271K |
| 76942 |
|
4,500 |
4,181 |
$268K |
| Q5111 |
Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg |
167 |
73 |
$264K |
| 84702 |
|
20,200 |
17,192 |
$262K |
| 90792 |
Psychiatric diagnostic evaluation with medical services |
3,798 |
3,539 |
$262K |
| 0002A |
|
8,706 |
7,857 |
$260K |
| 77062 |
|
3,074 |
3,012 |
$260K |
| J2704 |
Injection, propofol, 10 mg |
52,549 |
42,572 |
$253K |
| 81025 |
|
42,787 |
39,540 |
$253K |
| 93325 |
|
3,618 |
3,449 |
$250K |
| J9999 |
Not otherwise classified, antineoplastic drugs |
4,180 |
2,690 |
$249K |
| 86803 |
|
29,166 |
28,217 |
$248K |
| 90750 |
|
3,410 |
3,380 |
$248K |
| 83970 |
|
14,212 |
13,548 |
$242K |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
15,743 |
10,273 |
$242K |
| 74018 |
|
5,982 |
5,336 |
$242K |
| 58300 |
|
1,260 |
1,194 |
$239K |
| 70498 |
|
3,585 |
3,400 |
$238K |
| 82784 |
|
31,999 |
27,343 |
$236K |
| 83690 |
|
47,398 |
42,179 |
$236K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
65,681 |
50,845 |
$231K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
11,266 |
10,754 |
$230K |
| 17110 |
|
1,454 |
1,351 |
$229K |
| 82607 |
|
33,418 |
32,077 |
$229K |
| 19083 |
|
313 |
303 |
$229K |
| 97760 |
|
5,038 |
4,717 |
$227K |
| 77290 |
|
886 |
826 |
$226K |
| 73130 |
|
9,099 |
7,848 |
$220K |
| J0574 |
Buprenorphine/naloxone, oral, greater than 6 mg, but less than or equal to 10 mg buprenorphine |
5,358 |
2,707 |
$217K |
| 80053 |
Comprehensive metabolic panel |
200,324 |
157,077 |
$213K |
| 72170 |
|
5,114 |
4,841 |
$213K |
| 73110 |
|
7,584 |
6,512 |
$210K |
| 93976 |
|
1,990 |
1,925 |
$208K |
| J9070 |
Cyclophosphamide, 100 mg |
1,506 |
687 |
$205K |
| 87040 |
|
15,244 |
12,999 |
$205K |
| 20553 |
|
1,636 |
1,477 |
$203K |
| 87522 |
Neg quan hep c or qual rna |
7,071 |
6,667 |
$201K |
| 90715 |
|
14,518 |
14,172 |
$201K |
| 80050 |
General health panel |
13,874 |
13,109 |
$201K |
| 83550 |
|
43,475 |
41,385 |
$200K |
| 85610 |
|
89,148 |
68,433 |
$199K |
| 74174 |
|
2,155 |
2,040 |
$198K |
| 82803 |
|
12,228 |
10,163 |
$196K |
| 96409 |
|
3,879 |
2,587 |
$195K |
| J1650 |
Injection, enoxaparin sodium, 10 mg |
12,434 |
4,716 |
$192K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
3,068 |
2,605 |
$190K |
| 92523 |
|
1,592 |
1,478 |
$189K |
| 77061 |
|
1,888 |
1,855 |
$186K |
| 92552 |
|
1,866 |
1,844 |
$184K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
1,704 |
1,674 |
$183K |
| ATP16 |
|
23,620 |
16,707 |
$182K |
| 70486 |
|
2,894 |
2,715 |
$182K |
| 92611 |
|
2,016 |
1,945 |
$180K |
| 76604 |
|
2,182 |
2,063 |
$180K |
| J1050 |
Injection, medroxyprogesterone acetate, 1 mg |
4,305 |
4,229 |
$180K |
| 96411 |
|
4,205 |
2,758 |
$178K |
| 73502 |
|
7,772 |
7,344 |
$177K |
| 72100 |
|
6,999 |
6,808 |
$175K |
| 86480 |
|
3,673 |
3,573 |
$174K |
| 76870 |
|
1,894 |
1,812 |
$173K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
15,226 |
14,781 |
$173K |
| 77065 |
Tomosynthesis, mammo |
4,831 |
4,370 |
$171K |
| ATP17 |
|
24,171 |
20,897 |
$170K |
| 86140 |
|
50,466 |
45,216 |
$164K |
| 44970 |
|
50 |
50 |
$160K |
| 93880 |
|
2,443 |
2,350 |
$157K |
| 87070 |
|
26,591 |
24,471 |
$154K |
| 87077 |
|
26,389 |
24,458 |
$154K |
| 87497 |
|
8,348 |
5,337 |
$150K |
| 88346 |
|
1,713 |
1,531 |
$149K |
| 72082 |
|
2,623 |
2,551 |
$148K |
| 29075 |
|
644 |
557 |
$148K |
| 0124A |
|
5,454 |
5,308 |
$147K |
| 84403 |
|
10,325 |
9,929 |
$145K |
| 77280 |
|
1,175 |
1,086 |
$144K |
| J9201 |
Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg |
1,179 |
560 |
$143K |
| 29705 |
|
802 |
717 |
$142K |
| 95819 |
|
544 |
502 |
$142K |
| 86360 |
|
7,087 |
6,719 |
$142K |
| J2796 |
Injection, romiplostim, 10 micrograms |
328 |
73 |
$141K |
| 87340 |
|
19,703 |
18,994 |
$140K |
| 87186 |
|
23,392 |
21,502 |
$140K |
| 96368 |
|
2,928 |
1,850 |
$132K |
| 84439 |
|
24,049 |
22,661 |
$132K |
| 88360 |
|
1,662 |
1,555 |
$131K |
| 99385 |
|
2,171 |
2,073 |
$129K |
| Q5107 |
Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg |
1,251 |
439 |
$129K |
| 90846 |
Family psychotherapy without the patient present, 50 minutes |
1,355 |
1,002 |
$127K |
| 96133 |
|
314 |
304 |
$127K |
| 73560 |
|
5,496 |
4,867 |
$126K |
| 95885 |
|
864 |
828 |
$126K |
| 83516 |
|
11,614 |
10,372 |
$126K |
| 92508 |
Group treatment of speech, language, voice, communication, and/or auditory processing disorder |
1,282 |
465 |
$125K |
| 88304 |
|
4,189 |
3,908 |
$124K |
| 86359 |
|
7,713 |
7,258 |
$123K |
| 41899 |
Unlisted procedure, dentoalveolar structures |
140 |
94 |
$122K |
| 10060 |
|
784 |
720 |
$121K |
| 11981 |
|
584 |
556 |
$121K |
| 0071A |
|
2,761 |
2,683 |
$119K |
| 11056 |
|
1,227 |
1,112 |
$119K |
| 83540 |
|
35,704 |
34,058 |
$119K |
| 88112 |
|
3,535 |
3,376 |
$118K |
| 58301 |
|
644 |
622 |
$116K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
36,924 |
28,732 |
$114K |
| 73590 |
|
5,077 |
4,485 |
$113K |
| 64721 |
|
151 |
150 |
$112K |
| 81001 |
|
64,702 |
58,170 |
$111K |
| 96118 |
|
184 |
170 |
$111K |
| 86900 |
|
44,209 |
35,355 |
$110K |
| J9299 |
Injection, nivolumab, 1 mg |
148 |
64 |
$109K |
| 86923 |
|
4,982 |
3,717 |
$109K |
| 74019 |
|
1,910 |
1,755 |
$108K |
| 88342 |
|
8,963 |
8,457 |
$108K |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
58,489 |
52,061 |
$107K |
| 29881 |
|
63 |
63 |
$107K |
| 90837 |
Psychotherapy, 53 minutes with patient |
962 |
583 |
$106K |
| 86706 |
|
15,074 |
14,476 |
$105K |
| 86901 |
|
44,155 |
35,312 |
$104K |
| 93923 |
|
2,023 |
1,920 |
$103K |
| 77338 |
|
1,062 |
1,018 |
$103K |
| 87081 |
|
17,759 |
16,635 |
$103K |
| 86356 |
|
7,759 |
7,241 |
$101K |
| 82746 |
|
14,506 |
13,720 |
$98K |
| 87806 |
|
5,653 |
5,273 |
$98K |
| J0131 |
Injection, acetaminophen, not otherwise specified,10 mg |
4,074 |
3,509 |
$97K |
| 96402 |
|
3,636 |
3,286 |
$97K |
| 76857 |
|
1,669 |
1,522 |
$96K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
2,249 |
2,094 |
$96K |
| 73700 |
|
1,259 |
1,148 |
$95K |
| 84153 |
|
11,296 |
10,819 |
$93K |
| 85379 |
|
13,191 |
12,149 |
$92K |
| ATP03 |
|
32,758 |
27,888 |
$91K |
| 97166 |
|
1,462 |
1,371 |
$90K |
| 77002 |
|
1,483 |
1,399 |
$89K |
| 58571 |
|
24 |
24 |
$88K |
| 58100 |
|
423 |
400 |
$88K |
| 88341 |
|
3,809 |
3,558 |
$88K |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
46,273 |
40,443 |
$87K |
| 73140 |
|
3,199 |
2,905 |
$87K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
31,277 |
25,823 |
$86K |
| 72040 |
|
2,561 |
2,476 |
$86K |
| P9016 |
Red blood cells, leukocytes reduced, each unit |
3,441 |
2,155 |
$86K |
| 85730 |
|
20,177 |
17,301 |
$86K |
| 86235 |
|
2,913 |
2,706 |
$86K |
| J1170 |
Injection, hydromorphone, up to 4 mg |
24,418 |
15,650 |
$85K |
| 84146 |
|
7,376 |
6,955 |
$85K |
| 74178 |
|
572 |
554 |
$85K |
| 94060 |
|
1,775 |
1,687 |
$84K |
| 99495 |
|
1,030 |
1,001 |
$84K |
| 99173 |
|
2,666 |
2,561 |
$84K |
| J1644 |
Injection, heparin sodium, per 1000 units |
11,639 |
6,811 |
$81K |
| 76815 |
Ultrasound, pregnant uterus, real time with image documentation, limited |
1,602 |
1,437 |
$80K |
| 85652 |
|
49,463 |
45,397 |
$79K |
| 90677 |
|
3,677 |
3,576 |
$79K |
| 87799 |
|
5,729 |
4,172 |
$79K |
| 73562 |
|
2,733 |
2,501 |
$79K |
| 80197 |
|
18,153 |
10,577 |
$77K |
| 82570 |
|
35,528 |
32,917 |
$76K |
| J3489 |
Injection, zoledronic acid, 1 mg |
2,640 |
2,527 |
$76K |
| 83883 |
|
8,525 |
7,438 |
$76K |
| 82670 |
|
4,432 |
4,131 |
$76K |
| 82378 |
|
10,069 |
8,369 |
$75K |
| 80061 |
Lipid panel |
102,516 |
99,109 |
$74K |
| 90461 |
|
23,465 |
23,200 |
$74K |
| 96523 |
|
2,226 |
1,704 |
$74K |
| 90696 |
|
4,183 |
4,134 |
$74K |
| 83001 |
|
6,380 |
6,115 |
$74K |
| 12011 |
|
394 |
374 |
$74K |
| J0690 |
Injection, cefazolin sodium, 500 mg |
24,202 |
19,460 |
$72K |
| ATP07 |
|
12,002 |
10,595 |
$72K |
| 90935 |
Hemodialysis procedure with single evaluation by a physician |
279 |
104 |
$71K |
| 99496 |
|
767 |
737 |
$71K |
| 73090 |
|
3,096 |
2,649 |
$71K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
64,848 |
59,009 |
$70K |
| 73080 |
|
3,132 |
2,891 |
$70K |
| 86003 |
|
2,232 |
2,032 |
$70K |
| 77066 |
Tomosynthesis, mammo |
4,711 |
4,585 |
$69K |
| 84100 |
|
91,560 |
65,223 |
$69K |
| 77332 |
|
767 |
666 |
$68K |
| 72156 |
|
432 |
411 |
$67K |
| 86704 |
|
8,933 |
8,510 |
$67K |
| ATP09 |
|
12,550 |
8,756 |
$67K |
| 73060 |
|
2,065 |
1,846 |
$67K |
| 85007 |
|
30,868 |
20,429 |
$66K |
| 12001 |
|
392 |
372 |
$66K |
| 88173 |
|
1,399 |
1,338 |
$65K |
| 73552 |
|
3,294 |
3,041 |
$65K |
| 81003 |
|
47,613 |
43,907 |
$65K |
| 96417 |
|
8,973 |
5,496 |
$64K |
| 93797 |
|
1,514 |
484 |
$64K |
| 0054A |
|
3,118 |
2,877 |
$64K |
| J2543 |
Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) |
2,733 |
1,406 |
$64K |
| 0072A |
|
1,416 |
1,416 |
$64K |
| ATP18 |
|
9,114 |
7,606 |
$63K |
| ATP10 |
|
11,377 |
9,304 |
$63K |
| 94729 |
|
3,930 |
3,764 |
$63K |
| 87641 |
|
2,756 |
2,639 |
$63K |
| 90691 |
|
2,682 |
2,655 |
$63K |
| 96376 |
|
14,712 |
10,978 |
$62K |
| 73221 |
|
295 |
280 |
$62K |
| 0004A |
|
2,315 |
2,188 |
$61K |
| 82105 |
|
7,227 |
6,708 |
$61K |
| 86038 |
|
8,835 |
8,488 |
$61K |
| ATP11 |
|
10,864 |
9,488 |
$61K |
| 87517 |
|
3,040 |
2,849 |
$61K |
| 36561 |
|
82 |
79 |
$60K |
| Q0139 |
Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (for esrd on dialysis) |
224 |
153 |
$58K |
| 83002 |
|
4,881 |
4,692 |
$58K |
| G0297 |
Low dose ct scan (ldct) for lung cancer screening |
622 |
603 |
$57K |
| 99386 |
|
1,134 |
1,103 |
$57K |
| 90746 |
|
3,114 |
3,047 |
$57K |
| 11055 |
|
567 |
524 |
$56K |
| 82043 |
|
27,080 |
25,652 |
$56K |
| 86832 |
|
425 |
397 |
$56K |
| J0248 |
Injection, remdesivir, 1 mg |
157 |
77 |
$55K |
| J0585 |
Injection, onabotulinumtoxina, 1 unit |
88 |
81 |
$55K |
| 92526 |
|
616 |
382 |
$55K |
| 51705 |
|
510 |
468 |
$54K |
| 77470 |
|
203 |
190 |
$53K |
| 86787 |
|
5,616 |
5,389 |
$53K |
| 77049 |
|
181 |
178 |
$53K |
| 76937 |
|
2,576 |
2,379 |
$52K |
| 99383 |
|
617 |
600 |
$52K |
| 87205 |
|
17,889 |
16,343 |
$51K |
| 84165 |
|
13,814 |
12,458 |
$51K |
| 87902 |
|
457 |
439 |
$50K |
| 85013 |
|
12,695 |
12,579 |
$50K |
| 73070 |
|
1,386 |
1,161 |
$50K |
| 77385 |
|
305 |
24 |
$50K |
| 11982 |
|
287 |
286 |
$49K |
| 46607 |
|
76 |
72 |
$49K |
| 99188 |
|
3,083 |
3,037 |
$48K |
| J2060 |
Injection, lorazepam, 2 mg |
11,869 |
8,590 |
$48K |
| G0108 |
Diabetes outpatient self-management training services, individual, per 30 minutes |
1,385 |
1,226 |
$47K |
| 86765 |
|
5,305 |
5,147 |
$47K |
| 88313 |
|
2,019 |
1,922 |
$47K |
| J3475 |
Injection, magnesium sulfate, per 500 mg |
17,938 |
13,692 |
$46K |
| 84480 |
|
5,985 |
5,631 |
$45K |
| 29065 |
|
173 |
143 |
$45K |
| 87338 |
|
4,754 |
4,649 |
$45K |
| 83520 |
|
4,622 |
4,043 |
$45K |
| 99443 |
|
6,435 |
5,783 |
$45K |
| 87400 |
|
2,365 |
2,312 |
$45K |
| 71271 |
|
1,600 |
1,568 |
$45K |
| 82330 |
|
5,373 |
4,174 |
$45K |
| 90714 |
|
2,340 |
2,288 |
$44K |
| 90732 |
|
3,336 |
3,267 |
$44K |
| 86160 |
|
3,462 |
3,247 |
$44K |
| 90480 |
|
3,528 |
3,461 |
$44K |
| J1944 |
Injection, aripiprazole lauroxil, (aristada), 1 mg |
40 |
40 |
$43K |
| 86039 |
|
6,570 |
6,332 |
$43K |
| 84270 |
|
3,184 |
3,098 |
$43K |
| 87625 |
|
2,670 |
2,614 |
$43K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
1,681 |
1,523 |
$42K |
| 90833 |
Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) |
2,134 |
1,921 |
$42K |
| 94726 |
|
1,633 |
1,549 |
$41K |
| C1769 |
Guide wire |
6,622 |
5,904 |
$41K |
| 86147 |
|
1,766 |
1,679 |
$41K |
| 86665 |
|
1,912 |
1,612 |
$40K |
| 95816 |
|
189 |
171 |
$40K |
| 96137 |
|
197 |
193 |
$40K |
| G0279 |
Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) |
2,682 |
2,619 |
$39K |
| 86762 |
|
3,473 |
3,370 |
$39K |
| 88184 |
|
1,420 |
1,272 |
$38K |
| 90472 |
Immunization administration, each additional vaccine (list separately) |
16,332 |
16,065 |
$38K |
| 64493 |
|
82 |
77 |
$38K |
| 86355 |
|
2,367 |
2,192 |
$38K |
| 91010 |
|
55 |
54 |
$38K |
| 86708 |
|
4,584 |
4,399 |
$38K |
| 90662 |
|
10,846 |
10,624 |
$37K |
| 87209 |
|
3,277 |
3,124 |
$37K |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
17,080 |
15,246 |
$37K |
| 77072 |
|
1,278 |
1,248 |
$36K |
| S0020 |
Injection, bupivicaine hydrochloride, 30 ml |
1,509 |
1,224 |
$35K |
| 73523 |
|
815 |
801 |
$35K |
| 82533 |
|
4,234 |
3,570 |
$35K |
| 11719 |
|
2,417 |
2,344 |
$35K |
| 87102 |
|
6,451 |
5,918 |
$34K |
| 47000 |
|
117 |
107 |
$34K |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
4,318 |
3,224 |
$34K |
| 96132 |
|
328 |
316 |
$34K |
| 86833 |
|
300 |
269 |
$34K |
| 72158 |
|
356 |
342 |
$34K |
| 72070 |
|
1,278 |
1,245 |
$33K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
11,142 |
8,552 |
$33K |
| 0051A |
|
843 |
831 |
$33K |
| 83020 |
|
2,981 |
2,893 |
$33K |
| 78306 |
|
244 |
226 |
$33K |
| 87808 |
|
3,553 |
3,414 |
$33K |
| 93321 |
|
738 |
708 |
$32K |
| J0834 |
Injection, cosyntropin, 0.25 mg |
508 |
477 |
$32K |
| 91322 |
|
1,677 |
1,631 |
$31K |
| ATP23 |
|
3,422 |
2,439 |
$31K |
| 82785 |
|
2,755 |
2,639 |
$31K |
| 20680 |
|
27 |
24 |
$31K |
| J9145 |
Injection, daratumumab, 10 mg |
47 |
12 |
$31K |
| 27447 |
|
12 |
12 |
$30K |
| 83615 |
|
40,105 |
28,504 |
$30K |
| 86618 |
|
3,080 |
2,951 |
$30K |
| 96116 |
|
227 |
219 |
$30K |
| 36902 |
|
33 |
26 |
$30K |
| 70548 |
|
361 |
349 |
$29K |
| 85045 |
|
14,468 |
11,251 |
$29K |
| 0081A |
|
682 |
682 |
$29K |
| 99397 |
|
890 |
797 |
$29K |
| Q3014 |
Telehealth originating site facility fee |
19,237 |
16,919 |
$29K |
| 93320 |
|
1,566 |
1,505 |
$29K |
| 49083 |
|
83 |
51 |
$29K |
| 86677 |
|
2,934 |
2,831 |
$28K |
| 84425 |
|
2,528 |
2,448 |
$28K |
| 93225 |
|
737 |
654 |
$28K |
| 19301 |
|
28 |
25 |
$28K |
| 86141 |
|
4,276 |
4,034 |
$27K |
| 86301 |
|
2,735 |
2,231 |
$27K |
| 82550 |
|
15,320 |
13,254 |
$27K |
| 54161 |
|
12 |
12 |
$26K |
| 99382 |
|
332 |
317 |
$26K |
| 82627 |
|
1,620 |
1,571 |
$26K |
| 76817 |
Ultrasound, pregnant uterus, real time with image documentation, transvaginal |
731 |
686 |
$26K |
| 82232 |
|
6,002 |
5,008 |
$26K |
| 77001 |
|
478 |
439 |
$25K |
| 90670 |
|
17,337 |
17,111 |
$25K |
| A9575 |
Injection, gadoterate meglumine, 0.1 ml |
18,401 |
17,108 |
$25K |
| J0881 |
Injection, darbepoetin alfa, 1 microgram (non-esrd use) |
192 |
125 |
$25K |
| 86334 |
|
3,483 |
3,157 |
$25K |
| 84156 |
|
15,412 |
13,409 |
$25K |
| J2997 |
Injection, alteplase recombinant, 1 mg |
343 |
282 |
$25K |
| 73100 |
|
620 |
485 |
$25K |
| J7512 |
Prednisone, immediate release or delayed release, oral, 1 mg |
8,278 |
5,173 |
$24K |
| 36415 |
Collection of venous blood by venipuncture |
169,422 |
140,087 |
$24K |
| J3370 |
Injection, vancomycin hcl, 500 mg |
6,477 |
3,674 |
$24K |
| J1630 |
Injection, haloperidol, up to 5 mg |
14,156 |
12,435 |
$24K |
| 84305 |
|
2,045 |
1,980 |
$24K |
| 96139 |
|
145 |
143 |
$23K |
| 86225 |
|
3,105 |
2,977 |
$23K |
| 81002 |
|
11,252 |
10,818 |
$23K |
| 95913 |
|
335 |
331 |
$23K |
| 86300 |
|
3,378 |
2,671 |
$23K |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
42,333 |
36,199 |
$23K |
| 86304 |
|
2,641 |
2,074 |
$22K |
| 87640 |
|
2,206 |
2,120 |
$22K |
| 0082A |
|
489 |
487 |
$22K |
| 82140 |
|
2,493 |
2,175 |
$21K |
| 80164 |
|
3,582 |
3,183 |
$21K |
| 70355 |
|
1,008 |
840 |
$21K |
| 82947 |
|
11,309 |
9,721 |
$21K |
| 93926 |
|
91 |
88 |
$21K |
| C1894 |
Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser |
4,585 |
4,126 |
$21K |
| 0154A |
|
591 |
573 |
$20K |
| 80299 |
|
2,129 |
1,735 |
$20K |
| 77059 |
|
14 |
14 |
$20K |
| 72081 |
|
246 |
241 |
$20K |
| 87116 |
|
2,976 |
2,447 |
$20K |
| C1887 |
Catheter, guiding (may include infusion/perfusion capability) |
2,629 |
2,412 |
$20K |
| 86255 |
|
2,075 |
1,832 |
$20K |
| 72110 |
|
608 |
597 |
$20K |
| 83993 |
|
1,524 |
1,466 |
$19K |
| 86727 |
|
2,246 |
2,179 |
$19K |
| J0171 |
Injection, adrenalin, epinephrine, 0.1 mg |
2,835 |
2,489 |
$19K |
| 99384 |
|
293 |
285 |
$19K |
| G0127 |
Trimming of dystrophic nails, any number |
5,255 |
5,018 |
$19K |
| 86709 |
|
2,593 |
2,484 |
$19K |
| 86735 |
|
2,407 |
2,321 |
$19K |
| G0439 |
Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit |
5,796 |
5,695 |
$19K |
| 86769 |
|
763 |
735 |
$19K |
| 86376 |
|
1,976 |
1,897 |
$19K |
| 86200 |
|
2,845 |
2,749 |
$19K |
| M0243 |
Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring |
66 |
66 |
$18K |
| 87177 |
|
3,301 |
3,141 |
$18K |
| 87206 |
|
4,266 |
3,612 |
$18K |
| J9041 |
Injection, bortezomib, 0.1 mg |
201 |
49 |
$18K |
| 82610 |
|
3,252 |
2,788 |
$18K |
| 74246 |
|
120 |
120 |
$18K |
| 88312 |
|
1,523 |
1,468 |
$18K |
| 87045 |
|
3,172 |
3,014 |
$18K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
4,581 |
4,047 |
$18K |
| 85240 |
|
1,337 |
1,251 |
$18K |
| 87046 |
|
3,158 |
3,001 |
$18K |
| 83010 |
|
2,756 |
2,452 |
$18K |
| 58661 |
|
12 |
12 |
$18K |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
14,001 |
11,143 |
$18K |
| 72050 |
|
509 |
494 |
$17K |
| 83021 |
|
1,165 |
1,135 |
$17K |
| G0498 |
Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted living) using a portable pump provided by the office/clinic, includes follow up office/clinic visit at the conclusion of the infusion |
714 |
407 |
$17K |
| 82088 |
|
771 |
741 |
$17K |
| 90632 |
|
771 |
753 |
$17K |
| 87529 |
|
739 |
718 |
$17K |
| 90836 |
|
1,269 |
1,051 |
$17K |
| J2795 |
Injection, ropivacaine hydrochloride, 1 mg |
6,252 |
5,579 |
$17K |
| 95910 |
|
180 |
179 |
$16K |
| 86800 |
|
2,037 |
1,939 |
$16K |
| 76376 |
|
226 |
208 |
$16K |
| 94727 |
|
721 |
691 |
$16K |
| 77077 |
|
490 |
475 |
$16K |
| 85384 |
|
3,175 |
2,544 |
$16K |
| 64483 |
|
28 |
27 |
$16K |
| 93924 |
|
176 |
166 |
$16K |
| ATP04 |
|
2,845 |
2,526 |
$16K |
| 83498 |
|
737 |
724 |
$16K |
| 86146 |
|
1,146 |
928 |
$16K |
| 73200 |
|
334 |
318 |
$15K |
| 93454 |
|
12 |
12 |
$15K |
| 87486 |
|
550 |
529 |
$15K |
| 87581 |
|
549 |
528 |
$15K |
| 86945 |
|
1,722 |
736 |
$15K |
| J0692 |
Injection, cefepime hydrochloride, 500 mg |
2,897 |
1,619 |
$15K |
| 19081 |
|
26 |
26 |
$15K |
| 90734 |
|
7,211 |
7,129 |
$15K |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
9,290 |
5,072 |
$15K |
| 91320 |
|
762 |
745 |
$15K |
| 82150 |
|
3,940 |
3,253 |
$15K |
| 85246 |
|
831 |
796 |
$15K |
| G0008 |
Administration of influenza virus vaccine |
14,951 |
14,771 |
$15K |
| 86664 |
|
1,307 |
1,236 |
$15K |
| 73000 |
|
414 |
366 |
$14K |
| 75561 |
|
66 |
62 |
$14K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
522 |
512 |
$14K |
| 96136 |
|
291 |
285 |
$14K |
| J1447 |
Injection, tbo-filgrastim, 1 microgram |
59 |
39 |
$14K |
| J9171 |
Injection, docetaxel, 1 mg |
79 |
52 |
$14K |
| 87184 |
|
2,765 |
2,548 |
$14K |
| 87269 |
|
1,815 |
1,728 |
$14K |
| 87272 |
|
1,815 |
1,727 |
$14K |
| 82010 |
|
2,186 |
1,856 |
$14K |
| 89051 |
|
3,328 |
2,893 |
$14K |
| 76981 |
|
164 |
162 |
$14K |
| J2370 |
Injection, phenylephrine hcl, up to 1 ml |
13,072 |
10,494 |
$14K |
| J7060 |
5% dextrose/water (500 ml = 1 unit) |
11,570 |
6,050 |
$14K |
| 78264 |
|
54 |
54 |
$14K |
| 91200 |
|
328 |
293 |
$14K |
| 0074A |
|
346 |
342 |
$13K |
| 87324 |
|
2,161 |
2,016 |
$13K |
| 85245 |
|
717 |
685 |
$13K |
| 86325 |
|
1,635 |
1,487 |
$13K |
| 86580 |
|
1,826 |
1,758 |
$13K |
| 76775 |
|
251 |
239 |
$13K |
| 86431 |
|
4,423 |
4,275 |
$13K |
| 29540 |
|
180 |
170 |
$13K |
| 0011A |
|
426 |
395 |
$13K |
| 83525 |
|
1,882 |
1,829 |
$13K |
| 82024 |
|
614 |
579 |
$13K |
| J1720 |
Injection, hydrocortisone sodium succinate, up to 100 mg |
2,052 |
1,563 |
$13K |
| 11042 |
Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm |
116 |
86 |
$13K |
| 0031A |
|
366 |
284 |
$13K |
| 80177 |
|
1,739 |
1,580 |
$12K |
| 83521 |
|
5,867 |
5,255 |
$12K |
| J0780 |
Injection, prochlorperazine, up to 10 mg |
1,619 |
1,185 |
$12K |
| 83921 |
|
1,514 |
1,467 |
$12K |
| 86644 |
|
1,217 |
1,138 |
$12K |
| 90620 |
|
168 |
166 |
$12K |
| 86357 |
|
830 |
764 |
$12K |
| 84432 |
|
1,522 |
1,437 |
$12K |
| 80175 |
|
1,812 |
1,687 |
$12K |
| 72146 |
|
171 |
161 |
$12K |
| J0640 |
Injection, leucovorin calcium, per 50 mg |
3,205 |
1,731 |
$12K |
| 71101 |
|
785 |
767 |
$12K |
| 84445 |
|
329 |
321 |
$12K |
| J0561 |
Injection, penicillin g benzathine, 100,000 units |
111 |
90 |
$12K |
| 99218 |
|
109 |
78 |
$12K |
| ATP02 |
|
3,007 |
2,573 |
$11K |
| J2426 |
Injection, paliperidone palmitate extended release (invega sustenna), 1 mg |
18 |
12 |
$11K |
| 93226 |
|
521 |
488 |
$11K |
| 82248 |
|
18,015 |
13,117 |
$11K |
| ATP19 |
|
1,651 |
1,276 |
$11K |
| 12002 |
|
65 |
61 |
$11K |
| J7999 |
Compounded drug, not otherwise classified |
2,502 |
1,973 |
$11K |
| ATP05 |
|
1,692 |
1,447 |
$11K |
| 72157 |
|
194 |
188 |
$11K |
| 86021 |
|
1,156 |
1,098 |
$11K |
| 87106 |
|
1,436 |
1,348 |
$10K |
| 87329 |
|
1,462 |
1,396 |
$10K |
| ATP13 |
|
1,409 |
1,160 |
$10K |
| 84244 |
|
845 |
817 |
$10K |
| C7900 |
Service for diagnosis, evaluation, or treatment of a mental health or substance use disorder, 15-29 minutes, provided remotely by hospital staff who are licensed to provide mental health services under applicable state law(s), when the patient is in their home, and there is no associated professional service |
1,368 |
889 |
$10K |
| 36589 |
|
55 |
52 |
$10K |
| 87075 |
|
1,334 |
1,208 |
$10K |
| J9045 |
Injection, carboplatin, 50 mg |
2,318 |
1,436 |
$9K |
| 80069 |
|
12,078 |
10,231 |
$9K |
| 80400 |
|
614 |
585 |
$9K |
| 82274 |
|
1,165 |
1,121 |
$9K |
| 78431 |
|
30 |
30 |
$9K |
| 86870 |
|
671 |
538 |
$9K |
| 38525 |
|
13 |
12 |
$9K |
| 29125 |
|
78 |
75 |
$9K |
| 93246 |
|
1,808 |
1,740 |
$9K |
| 86317 |
|
218 |
158 |
$9K |
| 81228 |
|
13 |
13 |
$9K |
| 90656 |
|
1,231 |
1,156 |
$9K |
| 94760 |
|
5,701 |
5,346 |
$9K |
| 82787 |
|
622 |
573 |
$9K |
| 84132 |
|
6,368 |
5,288 |
$9K |
| 83519 |
|
980 |
866 |
$8K |
| 74221 |
|
68 |
68 |
$8K |
| 0012A |
|
255 |
229 |
$8K |
| 29425 |
|
35 |
33 |
$8K |
| 73701 |
|
69 |
63 |
$8K |
| 90707 |
|
5,029 |
4,984 |
$8K |
| 95923 |
|
25 |
25 |
$8K |
| 84154 |
|
1,445 |
1,413 |
$8K |
| 80178 |
|
2,888 |
2,593 |
$8K |
| 74220 |
|
146 |
137 |
$8K |
| 87252 |
|
422 |
400 |
$8K |
| 73660 |
|
501 |
473 |
$8K |
| 84550 |
|
14,417 |
11,746 |
$8K |
| J2920 |
Injection, methylprednisolone sodium succinate, up to 40 mg |
2,420 |
1,783 |
$8K |
| J0295 |
Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm |
1,897 |
883 |
$7K |
| 27096 |
|
12 |
12 |
$7K |
| 90716 |
|
4,604 |
4,570 |
$7K |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
5,323 |
5,016 |
$7K |
| 69210 |
|
446 |
422 |
$7K |
| J0689 |
Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg |
888 |
534 |
$7K |
| 86592 |
|
2,578 |
2,456 |
$7K |
| 83090 |
|
800 |
768 |
$7K |
| 97763 |
|
423 |
293 |
$7K |
| 99417 |
Prolong home eval add 15m |
242 |
222 |
$7K |
| 0052A |
|
160 |
158 |
$7K |
| 84207 |
|
503 |
489 |
$7K |
| 88262 |
|
79 |
78 |
$7K |
| 88142 |
|
522 |
515 |
$7K |
| 99442 |
|
1,374 |
1,323 |
$7K |
| J9000 |
Injection, doxorubicin hydrochloride, 10 mg |
751 |
443 |
$6K |
| 87299 |
|
933 |
806 |
$6K |
| 87210 |
|
2,006 |
1,689 |
$6K |
| 17000 |
|
51 |
50 |
$6K |
| 29405 |
|
27 |
25 |
$6K |
| 77370 |
|
170 |
140 |
$6K |
| 73120 |
|
632 |
412 |
$6K |
| J0134 |
Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg |
2,388 |
2,153 |
$6K |
| 31575 |
|
40 |
36 |
$6K |
| 84630 |
|
730 |
710 |
$6K |
| 69209 |
|
99 |
95 |
$6K |
| 83930 |
|
1,655 |
1,477 |
$6K |
| 11100 |
|
25 |
25 |
$6K |
| 82962 |
|
22,744 |
19,611 |
$6K |
| A9552 |
Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries |
3,329 |
3,124 |
$6K |
| 20550 |
|
24 |
24 |
$6K |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
328 |
311 |
$6K |
| 82390 |
|
800 |
767 |
$6K |
| P9021 |
Red blood cells, each unit |
478 |
380 |
$5K |
| M0245 |
Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring |
24 |
22 |
$5K |
| 82103 |
|
646 |
630 |
$5K |
| 82810 |
|
1,139 |
996 |
$5K |
| 0003A |
|
236 |
231 |
$5K |
| M0220 |
Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring |
123 |
118 |
$5K |
| 77012 |
|
271 |
252 |
$5K |
| 0064A |
|
221 |
208 |
$5K |
| 95812 |
|
13 |
13 |
$5K |
| J9206 |
Injection, irinotecan, 20 mg |
1,251 |
649 |
$5K |
| 85520 |
|
677 |
586 |
$5K |
| 84295 |
|
4,165 |
3,334 |
$5K |
| 36410 |
|
4,519 |
4,154 |
$5K |
| 97533 |
|
28 |
14 |
$5K |
| 73503 |
|
168 |
160 |
$5K |
| C1751 |
Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) |
364 |
332 |
$5K |
| 11720 |
|
447 |
441 |
$5K |
| 82172 |
|
371 |
360 |
$5K |
| J7040 |
Infusion, normal saline solution, sterile (500 ml = 1 unit) |
3,391 |
2,194 |
$5K |
| 80202 |
|
677 |
312 |
$5K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
170 |
143 |
$5K |
| J1642 |
Injection, heparin sodium, (heparin lock flush), per 10 units |
194 |
171 |
$5K |
| 86705 |
|
688 |
667 |
$5K |
| Q0222 |
Injection, bebtelovimab, 175 mg |
92 |
92 |
$5K |
| 82977 |
|
4,869 |
4,433 |
$5K |
| 77523 |
|
124 |
13 |
$5K |
| G8978 |
Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals |
1,823 |
1,661 |
$5K |
| 88365 |
|
56 |
52 |
$5K |
| 38222 |
|
16 |
15 |
$5K |
| 88381 |
|
100 |
98 |
$5K |
| 96138 |
|
167 |
166 |
$5K |
| J8540 |
Dexamethasone, oral, 0.25 mg |
16,504 |
8,963 |
$5K |
| 99153 |
Mod sedat endo service >5yrs |
9,194 |
8,702 |
$5K |
| 62270 |
|
15 |
13 |
$5K |
| C7901 |
Service for diagnosis, evaluation, or treatment of a mental health or substance use disorder, 30-60 minutes, provided remotely by hospital staff who are licensed to provided mental health services under applicable state law(s), when the patient is in their home, and there is no associated professional service |
3,225 |
1,497 |
$5K |
| 84590 |
|
753 |
737 |
$4K |
| 84300 |
|
1,883 |
1,637 |
$4K |
| 77307 |
|
31 |
30 |
$4K |
| 0296T |
|
1,670 |
1,590 |
$4K |
| 87274 |
|
568 |
538 |
$4K |
| 87290 |
|
567 |
537 |
$4K |
| 83835 |
|
394 |
363 |
$4K |
| 10061 |
|
42 |
42 |
$4K |
| 0083A |
|
90 |
90 |
$4K |
| 80143 |
|
565 |
541 |
$4K |
| 83935 |
|
1,239 |
1,079 |
$4K |
| 80179 |
|
472 |
459 |
$4K |
| 82565 |
|
6,394 |
5,867 |
$4K |
| 20552 |
|
29 |
28 |
$4K |
| 85307 |
|
413 |
382 |
$4K |
| 11976 |
|
13 |
13 |
$4K |
| 80195 |
|
806 |
515 |
$4K |
| 0173A |
|
109 |
105 |
$4K |
| 11721 |
|
248 |
238 |
$4K |
| A9500 |
Technetium tc-99m sestamibi, diagnostic, per study dose |
4,508 |
4,298 |
$3K |
| 88311 |
|
828 |
788 |
$3K |
| 85300 |
|
453 |
402 |
$3K |
| 83789 |
|
354 |
325 |
$3K |
| 20605 |
|
27 |
24 |
$3K |
| 81240 |
|
164 |
150 |
$3K |
| 74175 |
|
149 |
140 |
$3K |
| 82310 |
|
4,472 |
4,219 |
$3K |
| 85303 |
|
353 |
327 |
$3K |
| 75572 |
|
54 |
52 |
$3K |
| 87563 |
|
165 |
155 |
$3K |
| J0461 |
Injection, atropine sulfate, 0.01 mg |
1,279 |
750 |
$3K |
| 86703 |
|
307 |
289 |
$3K |
| 85305 |
|
372 |
348 |
$3K |
| J0694 |
Injection, cefoxitin sodium, 1 gm |
126 |
65 |
$3K |
| M0247 |
Intravenous infusion, sotrovimab, includes infusion and post administration monitoring |
84 |
80 |
$3K |
| 82945 |
|
1,323 |
1,168 |
$3K |
| 90474 |
|
2,351 |
2,341 |
$3K |
| 58340 |
|
13 |
12 |
$3K |
| 86341 |
|
203 |
192 |
$3K |
| 84134 |
|
351 |
307 |
$3K |
| 84402 |
|
181 |
175 |
$3K |
| ATP12 |
|
478 |
394 |
$2K |
| 80156 |
|
388 |
372 |
$2K |
| 70543 |
|
12 |
12 |
$2K |
| M0222 |
Intravenous injection, bebtelovimab, includes injection and post administration monitoring |
17 |
17 |
$2K |
| 91120 |
|
13 |
13 |
$2K |
| 70487 |
|
25 |
24 |
$2K |
| 84466 |
|
326 |
303 |
$2K |
| G0103 |
Prostate cancer screening; prostate specific antigen test (psa) |
2,723 |
2,687 |
$2K |
| 82657 |
|
174 |
165 |
$2K |
| 76706 |
|
90 |
87 |
$2K |
| J0137 |
Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg |
1,352 |
1,213 |
$2K |
| P9035 |
Platelets, pheresis, leukocytes reduced, each unit |
117 |
37 |
$2K |
| 87807 |
|
210 |
201 |
$2K |
| 82180 |
|
293 |
283 |
$2K |
| 88331 |
|
191 |
173 |
$2K |
| 82085 |
|
470 |
431 |
$2K |
| 94010 |
|
72 |
70 |
$2K |
| G2211 |
Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) |
901 |
821 |
$2K |
| J3360 |
Injection, diazepam, up to 5 mg |
572 |
392 |
$2K |
| 96377 |
|
650 |
477 |
$2K |
| 72190 |
|
62 |
58 |
$2K |
| 93798 |
|
68 |
28 |
$2K |
| 96111 |
|
45 |
35 |
$2K |
| 84681 |
|
162 |
156 |
$2K |
| 85018 |
|
1,925 |
1,660 |
$2K |
| J3590 |
Unclassified biologics |
116 |
57 |
$2K |
| 82668 |
|
258 |
246 |
$2K |
| G0009 |
Administration of pneumococcal vaccine |
3,434 |
3,380 |
$2K |
| J9190 |
Injection, fluorouracil, 500 mg |
6,679 |
2,337 |
$2K |
| 95924 |
|
24 |
24 |
$2K |
| 72131 |
|
156 |
142 |
$2K |
| 87505 |
|
35 |
30 |
$2K |
| J7300 |
Intrauterine copper contraceptive (paragard) |
12 |
12 |
$2K |
| J0665 |
Injection, bupivicaine, not otherwise specified, 0.5 mg |
1,661 |
1,433 |
$2K |
| 99195 |
|
29 |
26 |
$2K |
| 83695 |
|
261 |
250 |
$1K |
| 0134A |
|
64 |
64 |
$1K |
| Q0091 |
Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory |
12,362 |
11,473 |
$1K |
| 76098 |
|
68 |
64 |
$1K |
| 88368 |
|
40 |
36 |
$1K |
| 93350 |
|
27 |
26 |
$1K |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
1,998 |
1,912 |
$1K |
| 84155 |
|
3,195 |
2,808 |
$1K |
| 99493 |
|
70 |
69 |
$1K |
| J2785 |
Injection, regadenoson, 0.1 mg |
2,539 |
2,432 |
$1K |
| 84144 |
|
91 |
85 |
$1K |
| 82379 |
|
177 |
161 |
$1K |
| J9267 |
Injection, paclitaxel, 1 mg |
2,941 |
1,394 |
$1K |
| J2272 |
Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg |
709 |
577 |
$1K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
214 |
198 |
$1K |
| S0028 |
Injection, famotidine, 20 mg |
192 |
157 |
$1K |
| J9370 |
Vincristine sulfate, 1 mg |
940 |
651 |
$1K |
| 93242 |
|
290 |
284 |
$1K |
| 91122 |
|
16 |
14 |
$1K |
| Q9966 |
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml |
2,613 |
2,354 |
$1K |
| J3411 |
Injection, thiamine hcl, 100 mg |
443 |
313 |
$1K |
| 86308 |
|
278 |
255 |
$1K |
| J1836 |
Injection, metronidazole, 10 mg |
448 |
348 |
$1K |
| 82270 |
|
408 |
385 |
$1K |
| ATP06 |
|
182 |
159 |
$1K |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
7,006 |
5,896 |
$1K |
| 86707 |
|
169 |
164 |
$1K |
| 85014 |
|
497 |
497 |
$1K |
| 95911 |
|
24 |
24 |
$1K |
| 88172 |
|
75 |
73 |
$963.51 |
| 80230 |
|
55 |
54 |
$938.70 |
| 82465 |
|
922 |
851 |
$938.48 |
| G0257 |
Unscheduled or emergency dialysis treatment for an esrd patient in a hospital outpatient department that is not certified as an esrd facility |
665 |
407 |
$914.14 |
| 84080 |
|
148 |
145 |
$881.32 |
| 82652 |
|
44 |
40 |
$852.34 |
| 94761 |
|
1,446 |
1,032 |
$845.39 |
| 86696 |
|
56 |
54 |
$840.60 |
| J1580 |
Injection, garamycin, gentamicin, up to 80 mg |
328 |
282 |
$827.03 |
| 0073A |
|
17 |
17 |
$779.79 |
| 84520 |
|
5,030 |
4,031 |
$779.57 |
| 82247 |
|
3,248 |
2,858 |
$773.11 |
| 87901 |
|
14 |
13 |
$763.56 |
| J2175 |
Injection, meperidine hydrochloride, per 100 mg |
939 |
897 |
$762.12 |
| 89060 |
|
238 |
224 |
$744.22 |
| J7507 |
Tacrolimus, immediate release, oral, 1 mg |
183 |
68 |
$741.33 |
| 82139 |
|
69 |
64 |
$734.54 |
| J2400 |
Injection, chloroprocaine hydrochloride, per 30 ml |
13 |
12 |
$712.70 |
| J0330 |
Injection, succinylcholine chloride, up to 20 mg |
6,759 |
4,280 |
$695.57 |
| 84460 |
|
6,634 |
6,312 |
$675.20 |
| 87260 |
|
383 |
333 |
$673.17 |
| 87279 |
|
385 |
335 |
$673.17 |
| 99152 |
|
8,565 |
8,198 |
$669.68 |
| S0119 |
Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) |
9,846 |
8,526 |
$666.78 |
| 82365 |
|
78 |
76 |
$661.55 |
| G0270 |
Medical nutrition therapy; reassessment and subsequent intervention(s) following second referral in same year for change in diagnosis, medical condition or treatment regimen (including additional hours needed for renal disease), individual, face to face with the patient, each 15 minutes |
53 |
52 |
$653.64 |
| 72220 |
|
39 |
39 |
$643.62 |
| 90473 |
|
21 |
21 |
$639.37 |
| J1596 |
Injection, glycopyrrolate, 0.1 mg |
55 |
50 |
$635.56 |
| 82985 |
|
107 |
104 |
$627.66 |
| 87350 |
|
109 |
106 |
$622.70 |
| 84145 |
|
496 |
450 |
$611.00 |
| 86256 |
|
84 |
66 |
$609.07 |
| 0111A |
|
13 |
13 |
$596.31 |
| Q9969 |
Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose |
1,395 |
1,347 |
$582.60 |
| 86695 |
|
56 |
54 |
$572.64 |
| 97164 |
|
29 |
27 |
$563.23 |
| 72202 |
|
28 |
27 |
$554.10 |
| M0223 |
Intravenous injection, bebtelovimab, includes injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency |
12 |
12 |
$550.50 |
| 90633 |
|
10,299 |
10,188 |
$545.32 |
| J2710 |
Injection, neostigmine methylsulfate, up to 0.5 mg |
2,855 |
2,532 |
$519.81 |
| 86008 |
|
281 |
258 |
$510.73 |
| 93041 |
|
868 |
506 |
$507.88 |
| 86880 |
|
201 |
192 |
$502.14 |
| 82525 |
|
52 |
52 |
$482.32 |
| 84450 |
|
5,780 |
5,469 |
$482.31 |
| 93010 |
Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only |
101 |
86 |
$475.29 |
| G0500 |
Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) |
5,165 |
5,023 |
$453.12 |
| 84235 |
|
14 |
13 |
$431.68 |
| 73600 |
|
33 |
29 |
$428.43 |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
13 |
13 |
$424.38 |
| 75635 |
|
14 |
14 |
$423.70 |
| 87427 |
|
57 |
53 |
$413.35 |
| 84446 |
|
55 |
52 |
$410.63 |
| 90621 |
|
27 |
26 |
$409.86 |
| 99494 |
|
63 |
61 |
$398.53 |
| 90688 |
|
694 |
690 |
$393.24 |
| 86645 |
|
30 |
28 |
$382.72 |
| 85613 |
|
84 |
82 |
$379.13 |
| 73620 |
|
57 |
40 |
$376.95 |
| 0053A |
|
14 |
13 |
$366.96 |
| C1729 |
Catheter, drainage |
273 |
220 |
$354.76 |
| 82164 |
|
44 |
41 |
$331.12 |
| G8979 |
Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
1,882 |
1,712 |
$323.53 |
| H0046 |
Mental health services, not otherwise specified |
15 |
13 |
$322.20 |
| 0034A |
|
16 |
16 |
$321.09 |
| 90682 |
|
17 |
17 |
$320.23 |
| J0688 |
Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg |
458 |
446 |
$312.91 |
| 82040 |
|
2,182 |
1,950 |
$307.57 |
| L4386 |
Walking boot, non-pneumatic, with or without joints, with or without interface material, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise |
1,554 |
1,457 |
$302.36 |
| 86682 |
|
29 |
26 |
$292.75 |
| 85306 |
|
32 |
31 |
$279.68 |
| J3371 |
Injection, vancomycin hcl (mylan), not therapeutically equivalent to j3370, 500 mg |
291 |
274 |
$278.05 |
| 82166 |
|
24 |
13 |
$272.48 |
| 86777 |
|
28 |
28 |
$258.20 |
| 99492 |
|
15 |
15 |
$256.01 |
| 82542 |
|
14 |
13 |
$255.00 |
| C1725 |
Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) |
903 |
830 |
$252.29 |
| 83718 |
|
39 |
37 |
$251.28 |
| 97163 |
|
17 |
16 |
$250.51 |
| 0121A |
|
112 |
104 |
$242.11 |
| 87899 |
|
29 |
26 |
$236.98 |
| G0438 |
Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit |
196 |
191 |
$233.06 |
| 82955 |
|
38 |
37 |
$231.12 |
| 82239 |
|
15 |
12 |
$229.58 |
| J0670 |
Injection, mepivacaine hydrochloride, per 10 ml |
605 |
569 |
$227.66 |
| 80169 |
|
69 |
61 |
$225.60 |
| 87181 |
|
70 |
66 |
$217.09 |
| 90713 |
|
379 |
372 |
$211.95 |
| 80183 |
|
26 |
25 |
$205.53 |
| 73650 |
|
13 |
12 |
$188.52 |
| J7510 |
Prednisolone oral, per 5 mg |
337 |
273 |
$184.29 |
| 84075 |
|
1,855 |
1,683 |
$174.06 |
| J1171 |
Injection, hydromorphone, 0.1 mg |
317 |
173 |
$173.71 |
| 83986 |
|
68 |
65 |
$170.46 |
| J2919 |
Injection, methylprednisolone sodium succinate, 5 mg |
444 |
291 |
$165.50 |
| 87207 |
|
49 |
39 |
$163.57 |
| J1790 |
Injection, droperidol, up to 5 mg |
262 |
219 |
$162.06 |
| 80159 |
|
25 |
24 |
$159.93 |
| 87339 |
|
21 |
21 |
$153.53 |
| 87341 |
|
28 |
28 |
$150.72 |
| 84481 |
|
14 |
12 |
$139.76 |
| J1805 |
Injection, esmolol hydrochloride, 10 mg |
199 |
149 |
$138.70 |
| 80158 |
|
25 |
12 |
$131.68 |
| 36416 |
|
12,036 |
11,748 |
$128.09 |
| 95992 |
|
54 |
38 |
$116.08 |
| 84436 |
|
90 |
87 |
$115.50 |
| A9541 |
Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries |
625 |
592 |
$111.63 |
| G0444 |
Annual depression screening, 5 to 15 minutes |
212 |
210 |
$108.62 |
| 84133 |
|
44 |
40 |
$105.61 |
| 80185 |
|
24 |
24 |
$101.46 |
| J2540 |
Injection, penicillin g potassium, up to 600,000 units |
20 |
12 |
$97.30 |
| 80201 |
|
15 |
14 |
$94.59 |
| 90710 |
|
4,240 |
4,192 |
$91.88 |
| 82272 |
|
39 |
37 |
$91.71 |
| 93356 |
|
84 |
82 |
$88.36 |
| 87305 |
|
14 |
13 |
$84.56 |
| G0442 |
Annual alcohol misuse screening, 5 to 15 minutes |
144 |
142 |
$73.53 |
| 86036 |
|
433 |
416 |
$66.81 |
| Q9950 |
Injection, sulfur hexafluoride lipid microspheres, per ml |
222 |
200 |
$56.73 |
| 86316 |
|
13 |
12 |
$55.05 |
| 96040 |
|
521 |
510 |
$44.03 |
| 84478 |
|
286 |
190 |
$31.26 |
| 99441 |
|
17 |
17 |
$30.68 |
| J3480 |
Injection, potassium chloride, per 2 meq |
838 |
651 |
$28.27 |
| J1815 |
Injection, insulin, per 5 units |
21 |
15 |
$27.02 |
| 80348 |
|
2,646 |
1,797 |
$26.90 |
| L3808 |
Wrist hand finger orthosis, rigid without joints, may include soft interface material; straps, custom fabricated, includes fitting and adjustment |
409 |
393 |
$24.31 |
| 86037 |
|
108 |
106 |
$22.27 |
| 00731 |
|
12 |
12 |
$18.53 |
| A9503 |
Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries |
333 |
312 |
$18.06 |
| J1920 |
Injection, labetalol hydrochloride, 5 mg |
170 |
129 |
$16.03 |
| J0280 |
Injection, aminophyllin, up to 250 mg |
32 |
28 |
$11.39 |
| G0145 |
Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision |
1,293 |
1,264 |
$6.48 |
| J0744 |
Injection, ciprofloxacin for intravenous infusion, 200 mg |
202 |
167 |
$4.80 |
| 96125 |
|
79 |
55 |
$4.63 |
| C9113 |
Injection, pantoprazole sodium, per vial |
605 |
381 |
$3.76 |
| J3420 |
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg |
3,289 |
2,839 |
$2.46 |
| J1940 |
Injection, furosemide, up to 20 mg |
2,210 |
1,602 |
$1.28 |
| Q0163 |
Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen |
2,835 |
1,747 |
$1.05 |
| J2003 |
Injection, lidocaine hydrochloride, 1 mg |
39 |
37 |
$0.32 |
| 90749 |
|
396 |
385 |
$0.10 |
| G1004 |
Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program |
6,875 |
5,520 |
$0.01 |
| 90648 |
|
13,127 |
12,970 |
$0.00 |
| L3010 |
Foot, insert, removable, molded to patient model, longitudinal arch support, each |
306 |
281 |
$0.00 |
| L3908 |
Wrist hand orthosis, wrist extension control cock-up, non molded, prefabricated, off-the-shelf |
871 |
835 |
$0.00 |
| 91300 |
|
14,642 |
11,372 |
$0.00 |
| J0735 |
Injection, clonidine hydrochloride, 1 mg |
174 |
168 |
$0.00 |
| J9060 |
Injection, cisplatin, powder or solution, 10 mg |
499 |
229 |
$0.00 |
| C1713 |
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) |
863 |
817 |
$0.00 |
| 80356 |
|
2,646 |
1,796 |
$0.00 |
| 76821 |
|
127 |
119 |
$0.00 |
| 90685 |
|
745 |
730 |
$0.00 |
| J1956 |
Injection, levofloxacin, 250 mg |
13 |
12 |
$0.00 |
| L3913 |
Hand finger orthosis, without joints, may include soft interface, straps, custom fabricated, includes fitting and adjustment |
458 |
429 |
$0.00 |
| 90700 |
|
4,079 |
4,029 |
$0.00 |
| L3807 |
Wrist hand finger orthosis, without joint(s), prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise |
352 |
344 |
$0.00 |
| J1953 |
Injection, levetiracetam, 10 mg |
179 |
141 |
$0.00 |
| J2720 |
Injection, protamine sulfate, per 10 mg |
26 |
24 |
$0.00 |
| G8984 |
Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals |
424 |
407 |
$0.00 |
| G0101 |
Cervical or vaginal cancer screening; pelvic and clinical breast examination |
14 |
14 |
$0.00 |
| C1758 |
Catheter, ureteral |
12 |
12 |
$0.00 |
| 80364 |
|
2,645 |
1,796 |
$0.00 |
| G8997 |
Swallowing functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
71 |
67 |
$0.00 |
| 91312 |
|
1,352 |
1,330 |
$0.00 |
| C1760 |
Closure device, vascular (implantable/insertable) |
53 |
51 |
$0.00 |
| G8985 |
Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
438 |
420 |
$0.00 |
| 80365 |
|
2,639 |
1,791 |
$0.00 |
| 78434 |
|
30 |
30 |
$0.00 |
| 80346 |
|
2,673 |
1,821 |
$0.00 |
| 76827 |
|
124 |
117 |
$0.00 |
| G8996 |
Swallowing functional limitation, current status at therapy episode outset and at reporting intervals |
71 |
67 |
$0.00 |
| Q9957 |
Injection, perflutren lipid microspheres, per ml |
97 |
95 |
$0.00 |
| 51702 |
|
90 |
79 |
$0.00 |
| J0736 |
Injection, clindamycin phosphate, 300 mg |
20 |
12 |
$0.00 |
| 51701 |
|
27 |
26 |
$0.00 |
| J0153 |
Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) |
134 |
126 |
$0.00 |
| P9045 |
Infusion, albumin (human), 5%, 250 ml |
13 |
12 |
$0.00 |
| G8989 |
Self care functional limitation, discharge status, at discharge from therapy or to end reporting |
32 |
27 |
$0.00 |
| L1832 |
Knee orthosis, adjustable knee joints (unicentric or polycentric), positional orthosis, rigid support, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise |
25 |
25 |
$0.00 |
| 99401 |
|
12 |
12 |
$0.00 |
| C8929 |
Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography |
13 |
12 |
$0.00 |
| 82653 |
|
12 |
12 |
$0.00 |
| U0001 |
Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel |
45 |
42 |
$0.00 |
| 90672 |
|
24 |
24 |
$0.00 |
| M0248 |
Intravenous infusion, sotrovimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency |
15 |
15 |
$0.00 |
| J2359 |
Injection, olanzapine, 0.5 mg |
26 |
13 |
$0.00 |
| 0151A |
|
12 |
12 |
$0.00 |
| 96113 |
|
13 |
13 |
$0.00 |
| 90680 |
|
11,322 |
11,204 |
$0.00 |
| 76820 |
|
128 |
120 |
$0.00 |
| J0360 |
Injection, hydralazine hcl, up to 20 mg |
674 |
598 |
$0.00 |
| G8982 |
Changing & maintaining body position functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
150 |
145 |
$0.00 |
| 90697 |
|
2,358 |
2,351 |
$0.00 |
| 90698 |
|
270 |
268 |
$0.00 |
| L4350 |
Ankle control orthosis, stirrup style, rigid, includes any type interface (e.g., pneumatic, gel), prefabricated, off-the-shelf |
432 |
418 |
$0.00 |
| 76825 |
|
123 |
117 |
$0.00 |
| 87493 |
|
278 |
255 |
$0.00 |
| Q0164 |
Prochlorperazine maleate, 5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
482 |
240 |
$0.00 |
| G0010 |
Administration of hepatitis b vaccine |
109 |
108 |
$0.00 |
| Q0221 |
Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), 600 mg |
12 |
12 |
$0.00 |
| L3906 |
Wrist hand orthosis, without joints, may include soft interface, straps, custom fabricated, includes fitting and adjustment |
27 |
26 |
$0.00 |
| 80329 |
|
276 |
252 |
$0.00 |
| G8987 |
Self care functional limitation, current status, at therapy episode outset and at reporting intervals |
245 |
221 |
$0.00 |
| 36591 |
|
291 |
229 |
$0.00 |
| 90723 |
|
9,034 |
8,921 |
$0.00 |
| 80320 |
|
1,188 |
988 |
$0.00 |
| G8988 |
Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
251 |
225 |
$0.00 |
| 90744 |
|
1,511 |
1,487 |
$0.00 |
| J0610 |
Injection, calcium gluconate (fresenius kabi), per 10 ml |
314 |
235 |
$0.00 |
| 86381 |
|
240 |
228 |
$0.00 |
| 96112 |
|
216 |
168 |
$0.00 |
| 80327 |
|
28 |
24 |
$0.00 |
| L3923 |
Hand finger orthosis, without joints, may include soft interface, straps, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise |
219 |
211 |
$0.00 |
| 91301 |
|
479 |
426 |
$0.00 |
| C1889 |
Implantable/insertable device, not otherwise classified |
82 |
79 |
$0.00 |
| J2470 |
Injection, pantoprazole sodium, 40 mg |
59 |
50 |
$0.00 |
| 80353 |
|
2,645 |
1,796 |
$0.00 |
| G8986 |
Carrying, moving & handling objects functional limitation, discharge status, at discharge from therapy or to end reporting |
194 |
190 |
$0.00 |
| C1819 |
Surgical tissue localization and excision device (implantable) |
13 |
12 |
$0.00 |
| G8980 |
Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting |
678 |
619 |
$0.00 |
| 80358 |
|
2,646 |
1,797 |
$0.00 |
| L8030 |
Breast prosthesis, silicone or equal, without integral adhesive |
13 |
13 |
$0.00 |
| A9540 |
Technetium tc-99m macroaggregated albumin, diagnostic, per study dose, up to 10 millicuries |
14 |
14 |
$0.00 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
141 |
134 |
$0.00 |
| A9555 |
Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries |
42 |
42 |
$0.00 |
| G0123 |
Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision |
31 |
30 |
$0.00 |
| J2305 |
Injection, nitroglycerin, 5 mg |
42 |
29 |
$0.00 |
| J0611 |
Injection, calcium gluconate (wg critical care), per 10 ml |
14 |
12 |
$0.00 |
| G8981 |
Changing & maintaining body position functional limitation, current status, at therapy episode outset and at reporting intervals |
142 |
139 |
$0.00 |
| 91303 |
|
300 |
224 |
$0.00 |
| 80324 |
|
2,645 |
1,796 |
$0.00 |
| L4360 |
Walking boot, pneumatic and/or vacuum, with or without joints, with or without interface material, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise |
135 |
132 |
$0.00 |
| L3933 |
Finger orthosis, without joints, may include soft interface, custom fabricated, includes fitting and adjustment |
50 |
48 |
$0.00 |
| L8000 |
Breast prosthesis, mastectomy bra, without integrated breast prosthesis form, any size, any type |
42 |
42 |
$0.00 |
| J0456 |
Injection, azithromycin, 500 mg |
12 |
12 |
$0.00 |
| A9585 |
Injection, gadobutrol, 0.1 ml |
24 |
24 |
$0.00 |
| G8998 |
Swallowing functional limitation, discharge status, at discharge from therapy or to end reporting |
13 |
13 |
$0.00 |
| 91307 |
|
33 |
17 |
$0.00 |
| 82435 |
|
28 |
27 |
$0.00 |
| L4205 |
Repair of orthotic device, labor component, per 15 minutes |
16 |
12 |
$0.00 |